SPYRE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.56 USD | +3.36% |
|
+3.55% | +55.95% |
| Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
| Apr. 19 | Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 221.4 | 377.3 | 234.3 | 27.67 | 775.2 | 1,352 | - | - |
| Enterprise Value (EV) 1 | 221.4 | 377.3 | 234.3 | 27.67 | 435.6 | 714.1 | 1,019 | 1,276 |
| P/E ratio | -3.12 x | -5.18 x | -4.75 x | -0.45 x | -0.44 x | -9.53 x | -11.6 x | -9.57 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 12.5 x | 11.9 x | 875 x | 198 x | 262 x | 5,407 x |
| EV / Revenue | - | - | 12.5 x | 11.9 x | 492 x | 105 x | 197 x | 5,103 x |
| EV / EBITDA | -2.77 x | -4.69 x | - | - | -1.8 x | -5.41 x | -6.45 x | - |
| EV / FCF | -3.3 x | -4.71 x | -4.32 x | - | -4.36 x | -5.05 x | -7.49 x | -8.34 x |
| FCF Yield | -30.3% | -21.2% | -23.2% | - | -22.9% | -19.8% | -13.4% | -12% |
| Price to Book | 3.7 x | 2.7 x | 2.79 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,159 | 1,917 | 1,973 | 2,460 | 36,021 | 40,279 | - | - |
| Reference price 2 | 191.0 | 196.8 | 118.8 | 11.25 | 21.52 | 33.56 | 33.56 | 33.56 |
| Announcement Date | 2/24/20 | 3/18/21 | 3/8/22 | 3/2/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 18.74 | 2.329 | 0.886 | 6.817 | 5.167 | 0.25 |
| EBITDA 1 | -79.92 | -80.48 | - | - | -241.6 | -132 | -158 | - |
| EBIT 1 | -80.33 | -81.48 | -65.65 | -84.78 | -242.3 | -156.6 | -166.3 | -195.2 |
| Operating Margin | - | - | -350.33% | -3,640.23% | -27,347.97% | -2,297.31% | -3,218.71% | -78,060% |
| Earnings before Tax (EBT) 1 | -78.25 | -80.89 | -65.66 | -83.95 | -338.8 | -140.4 | -160 | -189.3 |
| Net income 1 | -78.25 | -80.89 | -65.8 | -83.82 | -338.8 | -169.4 | -167.5 | -193.6 |
| Net margin | - | - | -351.14% | -3,598.75% | -38,238.15% | -2,485.32% | -3,241.16% | -77,450% |
| EPS 2 | -61.25 | -38.00 | -25.00 | -24.75 | -49.12 | -3.520 | -2.884 | -3.505 |
| Free Cash Flow 1 | -67.18 | -80.06 | -54.29 | - | -99.91 | -141.5 | -136 | -153 |
| FCF margin | - | - | -289.71% | - | -11,276.52% | -2,075.79% | -2,632.26% | -61,200% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/20 | 3/18/21 | 3/8/22 | 3/2/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.399 | 3.644 | 1.362 | 0.625 | 0.174 | 0.168 | 0.198 | 0.688 | - | - | - | 3.333 | - | 3.5 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.29 | -20.44 | -24.44 | -22.42 | -18.76 | -19.16 | -18.81 | -159.2 | -32.95 | -45.91 | -39.1 | -35.9 | -41.62 | -39.98 | - |
| Operating Margin | -1,450.54% | -560.98% | -1,794.49% | -3,587.68% | -10,778.74% | -11,405.95% | -9,497.98% | -23,146.22% | - | - | - | -1,077% | - | -1,142.29% | - |
| Earnings before Tax (EBT) 1 | -20.28 | -20.42 | -24.44 | -22.31 | -18.44 | -18.78 | -18.46 | -217.1 | -40.1 | -63.18 | -36.6 | -32.38 | -39.32 | -37.02 | - |
| Net income 1 | -20.31 | -20.45 | -24.44 | -22.32 | -18.23 | -18.82 | -18.42 | -217.1 | -40.11 | -63.18 | -42.18 | -39.04 | -44.88 | -43.3 | - |
| Net margin | -1,451.54% | -561.09% | -1,794.13% | -3,571.68% | -10,479.31% | -11,203.57% | -9,304.04% | -31,552.47% | - | - | - | -1,171.2% | - | -1,237.14% | - |
| EPS 2 | -7.750 | -7.750 | -9.250 | -6.750 | -4.750 | -4.500 | -5.000 | -56.75 | -9.340 | -4.050 | -1.168 | -0.8940 | -0.9600 | -0.9000 | -0.4000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/8/22 | 5/5/22 | 8/4/22 | 11/3/22 | 3/2/23 | 5/11/23 | 8/11/23 | 11/9/23 | 2/29/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | 340 | 638 | 333 | 76 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -67.2 | -80.1 | -54.3 | - | -99.9 | -142 | -136 | -153 |
| ROE (net income / shareholders' equity) | -123% | -80.9% | -58.8% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -97.3% | -66.1% | -48.5% | - | - | - | - | - |
| Assets 1 | 80.46 | 122.4 | 135.8 | - | - | - | - | - |
| Book Value Per Share | 51.70 | 72.90 | 42.50 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.49 | 4.28 | 0.57 | 0.04 | - | 3 | 1.5 | 2.5 |
| Capex / Sales | - | - | 3.06% | 1.63% | - | 44.01% | 29.03% | 1,000% |
| Announcement Date | 2/24/20 | 3/18/21 | 3/8/22 | 3/2/23 | 2/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
33.56
USD
Average target price
42
USD
Spread / Average Target
+25.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.95% | 1.35B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SYRE Stock
- Financials Spyre Therapeutics, Inc.
